Fundraising FoxOligomerix
White Plains, US · 4 known investors
Find your way into Oligomerix
Sign up to see every warm intro you have to Oligomerix
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Oligomerix team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Oligomerix is a biopharmaceutical company developing therapeutic compounds, with leadership focused on advancing drug candidates through clinical development stages.
Founders & leadership
ED
Eliot DavidowitzCo-founder
EJ
Eliot J. DavidowitzChief Scientific Officer, Co-Founder
DM
Dr. MoeFounder
DD
Dr. DavidowitzFounder
WE
William ErhardtExecutive
RF
Robert FoersterExecutive
Board
DD
David DantzkerBoard director
DD
Douglas DurandBoard director
JB
Jeffrey BluesteinBoard director
VM
Victor MicatiBoard director
Investors · 4
Counterview Capitallisted by Counterview CapitalNew York
How we know: Counterview Capital's portfolio page · the VCSheet dataset · Not right? Tell us
Also in the syndicate · 3
Durand Venture Associates, LLCleadWheatley MedTech Partners, L.P.leadWheatley New York Partners LPlead
Funding
SEC filings, press & company announcements$5.6M disclosed across 4 of 6 rounds · 2012–2024
- $2.7MSeries B ExtensionJun 2022 · 2 sourcesSource ↗
- Undisclosed amountSeries AApr 2012
Durand Venture Associates, LLC (lead), Wheatley MedTech Partners, L.P. (lead), Wheatley New York Partners LP (lead)
Source ↗
▶$75KraisedDec 2024 · 3 investors · PharmaceuticalsRule 506(b)
▶$75KraisedDec 2024 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Douglas DurandDirector
- William ErhardtExecutive Officer, Director
- Robert FoersterExecutive Officer, Director
- Jeffrey BluesteinDirector
- Eliot DavidowitzExecutive Officer, Director
- James MoeExecutive Officer, Director
- David DantzkerDirector
- Jack PasiniExecutive Officer, Director
- Offering amount
- $650K
- Amount sold
- $75K
- First sale
- Nov 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.4MraisedMar 2022 · 12 investors · PharmaceuticalsRule 506(b)
▶$2.4MraisedMar 2022 · 12 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey BluesteinDirector
- Robert ForesterExecutive Officer
- Douglas DurandDirector
- Jack PasiniDirector
- James MoeExecutive Officer, Director
- David DantzkerDirector
- William ErhardtDirector
- Victor MicatiDirector
- Eliot DavidowitzDirector
- Offering amount
- $3.5M
- Amount sold
- $2.4M
- Proceeds to insiders
- $650K
- First sale
- Mar 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$400KraisedApr 2015 · 2 investors · PharmaceuticalsRule 506(b)
▶$400KraisedApr 2015 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey BluesteinDirector
- Douglas DurandDirector
- Jack PasiniDirector
- James MoeExecutive Officer, Director
- David DantzkerDirector
- Victor MicatiDirector
- Offering amount
- $3M
- Amount sold
- $400K
- Proceeds to insiders
- $200K
- First sale
- Apr 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.7MofferedMar 2012 · PharmaceuticalsRule 506(b)
▶$2.7MofferedMar 2012 · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David DantzkerDirector
- Douglas DurandDirector
- James MoeExecutive Officer, Director
- Jack PasiniDirector
- Victor MicatiDirector
- Offering amount
- $2.7M
- Minimum investment
- $25K
- Proceeds to insiders
- $94.5K
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 12 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $3.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $2.2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $2.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $499.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $302.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2013 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2010 | $1.6M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2009 | $323.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2007 | $233.6K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Oligomerix do?
- Oligomerix is a biopharmaceutical company developing therapeutic compounds, with leadership focused on advancing drug candidates through clinical development stages.
- Who founded Oligomerix?
- Oligomerix was founded by Eliot Davidowitz, James Moe, Eliot J. Davidowitz, Dr. Moe, Dr. Davidowitz.
- Who are Oligomerix's investors?
- Oligomerix's investors include Counterview Capital.
- How much funding has Oligomerix raised?
- Oligomerix has disclosed $5.6M raised across 4 of its 6 known rounds.
- Where is Oligomerix headquartered?
- Oligomerix is headquartered in White Plains, US.